Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

HGHAX Hartford Healthcare A

  • Fund
  • HGHAX
  • Price as of: Mar 22, 2019
  • $33.90
  • - $0.91
  • - 2.61%
  • Category
  • Health & Biotech Equities

HGHAX - Profile

Vitals

  • YTD Return 12.7%
  • 3 Yr Annualized Return 3.5%
  • 5 Yr Annualized Return 0.7%
  • Net Assets $1.37 B
  • Holdings in Top 10 38.4%

52 WEEK LOW AND HIGH

$33.90
$28.19
$38.58

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.28%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 27.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,000

IRA

$2,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 12.7%
  • 3 Yr Annualized Total Return 3.5%
  • 5 Yr Annualized Total Return 6.2%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.40%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name The Hartford Healthcare Fund
  • Fund Family Name Hartford Mutual Funds
  • Inception Date May 01, 2000
  • Shares Outstanding N/A
  • Share Class A
  • Currency USD
  • Domiciled Country United States
  • Manager Ann C. Gallo

Fund Description

Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP ("Wellington Management"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.

HGHAX - Performance

Return Ranking - Trailing

Period HGHAX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 12.7% -14.9% 32.4% 30.36% 2
1 Yr -1.0% -18.7% 24.1% 66.67% 4
3 Yr 3.5% * -14.6% 25.1% 63.89% 4
5 Yr 0.7% * -10.4% 18.7% 55.14% 3
10 Yr 12.3% * -0.6% 22.2% 36.67% 2

* Annualized


Return Ranking - Calendar

Period HGHAX Return Category Return Low Category Return High Rank in Category (%) Quintile
2018 -10.3% -91.9% 19.2% 65.45% 4
2017 15.5% -15.0% 43.9% 54.55% 3
2016 -17.2% -29.8% 33.7% 64.55% 4
2015 -1.9% -20.4% 48.1% 48.18% 3
2014 18.1% -5.8% 31.5% 39.09% 2

Total Return Ranking - Trailing

Period HGHAX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 12.7% -14.9% 32.4% 30.63% 2
1 Yr -1.0% -18.7% 19.6% 66.36% 4
3 Yr 3.5% * -14.6% 25.1% 65.74% 4
5 Yr 6.2% * -5.8% 18.5% 52.34% 3
10 Yr 27.2% * 5.8% 68.7% 23.88% 2

* Annualized


Total Return Ranking - Calendar

Period HGHAX Return Category Return Low Category Return High Rank in Category (%) Quintile
2018 -10.3% -91.9% 19.2% 67.89% 4
2017 15.5% -15.0% 43.9% 56.88% 3
2016 -17.2% -25.1% 100.0% 66.97% 4
2015 14.4% -16.6% 79.8% 12.84% 1
2014 35.2% -5.8% 61.4% 52.29% 3

NAV & Total Return History

HGHAX - Holdings

Filings data as of: Jan 31, 2019

Concentration Analysis

HGHAX Category Low Category High HGHAX % Rank Quintile
Net Assets 1.37 B 15.5 M 47.6 B 17.86% 3
Number of Holdings 103 28 368 11.61% 2
Net Assets in Top 10 502 M 9.61 M 18.5 B 18.75% 3
Weighting of Top 10 38.4% 23.3% 76.6% 25.89% 4

Top 10 Holdings

  1. Bristol-Myers Squibb Company 3.36%
  2. Medtronic PLC 3.82%
  3. UnitedHealth Group Inc 6.90%
  4. Boston Scientific Corp 3.48%
  5. Eli Lilly and Co 3.45%
  6. Thermo Fisher Scientific Inc 3.28%
  7. Abbott Laboratories 5.15%
  8. Anthem Inc 3.15%
  9. Seattle Genetics Inc 2.97%
  10. Vertex Pharmaceuticals Inc 2.86%

Asset Allocation

Weighting Category Low Category High HGHAX % Rank Quintile
Stocks
97.49% 94.90% 99.99% 21.43% 4
Cash
2.51% 0.00% 5.09% 9.82% 2
Preferred Stocks
0.00% 0.00% 2.19% 9.82% 4
Other
0.00% -4.63% 2.65% 10.71% 4
Convertible Bonds
0.00% 0.00% 0.28% 2.68% 3
Bonds
0.00% 0.00% 4.69% 3.57% 3

Stock Sector Breakdown

Weighting Category Low Category High HGHAX % Rank Quintile
Healthcare
94.86% 14.35% 99.99% 21.43% 3
Technology
1.55% 0.00% 62.70% 13.39% 3
Industrials
0.60% 0.00% 10.23% 4.46% 2
Utilities
0.00% 0.00% 0.00% 0.89% 3
Real Estate
0.00% 0.00% 2.22% 3.57% 4
Financial Services
0.00% 0.00% 3.45% 9.82% 4
Energy
0.00% 0.00% 0.08% 1.79% 4
Communication Services
0.00% 0.00% 0.00% 0.89% 3
Consumer Defense
0.00% 0.00% 1.31% 8.93% 4
Consumer Cyclical
0.00% 0.00% 7.34% 8.93% 4
Basic Materials
0.00% 0.00% 0.53% 2.68% 4

Stock Geographic Breakdown

Weighting Category Low Category High HGHAX % Rank Quintile
US
83.76% 63.03% 99.54% 24.11% 3
Non US
13.73% 0.00% 36.96% 13.39% 3

HGHAX - Expenses

Operational Fees

HGHAX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 1.28% 0.10% 4.31% 42.86% 3
Management Fee 0.85% 0.09% 1.25% 5.36% 4
12b-1 Fee 0.25% 0.00% 1.00% 8.86% 2
Administrative Fee N/A 0.01% 0.40% N/A N/A

Sales Fees

HGHAX Fees (% of AUM) Category Low Category High HGHAX Rank Quintile
Front Load 5.50% 2.50% 5.75% 7.41% 3
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

HGHAX Fees (% of AUM) Category Low Category High HGHAX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HGHAX Fees (% of AUM) Category Low Category High HGHAX Rank Quintile
Turnover 27.00% 0.00% 699.00% 23.21% 2

HGHAX - Distributions

Dividend Yield Analysis

HGHAX Category Low Category High HGHAX % Rank Quintile
Dividend Yield 0.0% 0.00% 1.15% 46.38% 4

Dividend Distribution Analysis

HGHAX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

HGHAX Category Low Category High HGHAX % Rank Quintile
Net Income Ratio -0.40% -2.15% 1.44% 42.86% 3

Capital Gain Distribution Analysis

HGHAX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

HGHAX - Managers

Ann C. Gallo

Manager

Start Date

May 01, 2000

Tenure

18.84

Tenure Rank

3.1%

Ann C. Gallo, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 1998. Prior to that, Ann was a health care analyst with BT Alex. Brown (1995 — 1998). She was an investment banker and a health care analyst at Piper Jaffray in Minneapolis (1992 — 1995). Previously, she was a financial analyst with Citibank N.A. (1991 — 1992) and an accountant with Coopers & Lybrand (1987 — 1989). Ann received her MS from the Massachusetts Institute of Technology and her BS in accounting from Boston College.


Jean M. Hynes

Manager

Start Date

May 01, 2000

Tenure

18.84

Tenure Rank

3.1%

Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003. Jean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.


Robert L. Deresiewicz

Manager

Start Date

May 01, 2000

Tenure

18.84

Tenure Rank

3.1%

Robert L. Deresiewicz, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 2000. Prior to that, Bob was an Assistant Professor of Medicine at the Harvard Medical School, and an Associate Physician in the Division of Infectious Diseases at the Brigham and Women's Hospital (1990 — 1998). Bob received his MBA from the Harvard Business School (2000), his MD from the Mount Sinai School of Medicine, and his BA in biochemistry summa cum laude from Columbia University.


Tenure Analysis

Category Low

0.1

Category High

21.5

Category Average

9.75

Category Mode

4.2